NCT03801304View on ClinicalTrials.gov

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

January 4, 2021

Study Completion Date

February 23, 2022

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Atezolizumab

Atezolizumab in IV infusions

DRUG

Vinorelbine

Vinorelbine capsules

Trial Locations (13)

29609

CHRU de Brest - Hôpital Morvan, Brest

35033

CHU de Rennes, Rennes

83041

Hia Saint Anne, Toulon

85000

Ch La Roche Sur Yon, La Roche-sur-Yon

87042

CHU de Limoges - Hôpital DUPUYTREN, Limoges

94010

CH de Créteil, Créteil

Unknown

CH Aix en Provence, Aix-en-Provence

CLCC Caen, Caen

CH MEAUX, Meaux

CH Pringy, Pringy

CH Quimper, Quimper

CHU Rouen, Rouen

CH Saint-Brieuc, Saint-Brieuc

All Listed Sponsors

collaborator

Groupe Francais De Pneumo-Cancerologie

OTHER

collaborator

Roche Farma, S.A

INDUSTRY

collaborator

Pierre Fabre Medicament

INDUSTRY

lead

University Hospital, Brest

OTHER

NCT03801304 - Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter